Beijing Sunho Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Xinghao Pharmaceutical Co., Ltd. was founded in 2000. We have four research and development and production bases in Beijing, Zhongshan, and Changchun, and branch offices in the United States, Europe, and Hong Kong. The company was successfully listed on the Zhongguancun Third Board of the Shenzhen Stock Exchange in August 2007, with a securities code of 430017. As a national high-tech enterprise, Xinghao Pharmaceutical has undertaken a number of national science and technology and industrialization projects, and has won support from the Ministry of Industry and Information Technology, the Ministry of Science and Technology, the National Development and Reform Commission and other national projects for many times. Among them, the industrialized CMC/CMO public service platform jointly built with the Chinese Academy of Sciences Shanghai Institute of Materia Medica has won special support for the construction of the biomedical contract research and development and production service platform, marking that Xinghao has begun to enter the ranks of the national team of pharmaceutical preparations industrialization services. Xinghao Pharmaceutical's services focus on the validation batch, registration batch production, global application and commercial production of new and generic drugs. We are committed to providing customized research and production services for drug formulations throughout the entire lifecycle of the global pharmaceutical industry, from clinical early research to drug launch. With the accumulation of drug research and development technology and industrialization experience, Xinghao Pharmaceutical has formed multiple core advantages represented by slow and controlled release formulation technology, key technology for rapid release orally disintegrating tablets, and intelligent manufacturing technology for complex injections. Currently, there are 9 workshops with cGMP production capacity, including 19 production lines, covering various dosage forms such as small volume injections, freeze-dried powder injections, ordinary tablets, freeze-dried orally disintegrating tablets, and capsules. Non tumor terminal sterilized small volume injections, as well as anti-tumor small volume injections and freeze-dried powder injections, have been submitted for EU EMA and US FDA certification. Starting from the concept of "quality comes from design", combined with domestic and foreign regulations and guidelines such as ICH, the US FDA, the European Union, and the National Drug Administration, a sound production quality assurance system has been established, and a comprehensive information software management system has been constructed, such as LIMS system, IP guard system, WMS system, BMS system, MES system, etc., forming a visual closed-loop management from planning to compliant production, Ensures data integrity and authenticity throughout the entire process. In the past three years, Xinghao has provided CMC/CMO services to nearly a hundred pharmaceutical companies, including more than 30 innovative drugs. Today's Xinghao has a more thoughtful service philosophy, more professional service methods, more efficient service delivery, and more comprehensive service value! Xinghao Pharmaceutical always adheres to the corporate culture concept of "surpassing oneself and creating development together", driven by technological innovation, with the mission of promoting the evolution of China's new drug creation services to international first-class. We jointly build and share a high-end service platform for the internationalization of China's new drug creation CMC/CMO, and deeply explore multi-level and comprehensive one-stop cooperation such as contract research and development (CRO) services and marketing license holder (MAH) conversion services, Strive to become an excellent innovative international high-end pharmaceutical industry service provider!. |
| Headquarter | Beijing |
| Establish Date | 10/27/2000 |
| Listed Code | 430017.BJ |
| Listed Date | 5/31/2023 |
| Chairman | Yin Lan. |
| CEO | Yu Jizhong. |
| Website | www.sunho.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
